Literature DB >> 33671869

Sensitivity to Cisplatin in Head and Neck Cancer Cells Is Significantly Affected by Patient-Derived Cancer-Associated Fibroblasts.

Barbora Peltanova1, Marketa Liskova1, Jaromir Gumulec1, Martina Raudenska1,2,3, Hana Holcova Polanska1,2, Tomas Vaculovic4, David Kalfert5, Marek Grega6, Jan Plzak5, Jan Betka5, Michal Masarik1,2,7.   

Abstract

Cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components of the tumor stroma. CAFs can impact many important steps of cancerogenesis and may also influence treatment resistance. Some of these effects need the direct contact of CAFs and cancer cells, while some involve paracrine signals. In this study, we investigated the ability of head and neck squamous cell carcinomas (HNSCC) patient-derived CAFs to promote or inhibit the colony-forming ability of HNSCC cells. The effect of cisplatin on this promoting or inhibiting influence was also studied. The subsequent analysis focused on changes in the expression of genes associated with cancer progression. We found that cisplatin response in model HNSCC cancer cells was modified by coculture with CAFs, was CAF-specific, and different patient-derived CAFs had a different "sensitizing ratio". Increased expression of VEGFA, PGE2S, COX2, EGFR, and NANOG in cancer cells was characteristic for the increase of resistance. On the other hand, CCL2 expression was associated with sensitizing effect. Significantly higher amounts of cisplatin were found in CAFs derived from patients who subsequently experienced a recurrence. In conclusion, our results showed that CAFs could promote and/or inhibit colony-forming capability and cisplatin resistance in HNSCC cells via paracrine effects and subsequent changes in gene expression of cancer-associated genes in cancer cells.

Entities:  

Keywords:  cancer recurrence; cancer-associated fibroblasts; cisplatin; coculture; head and neck cancer; patient-derived cell cultures; treatment resistance

Mesh:

Substances:

Year:  2021        PMID: 33671869      PMCID: PMC7918851          DOI: 10.3390/ijms22041912

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  23 in total

1.  Drug therapy: Cetuximab or cisplatin in HNSCC?

Authors:  Lisa Hutchinson
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

2.  Suppression of tumor formation in vivo by expression of the JE gene in malignant cells.

Authors:  B J Rollins; M E Sunday
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

Review 3.  Epithelial-stromal interaction in squamous cell epithelium-derived tumors: an important new player in the control of tumor biological properties.

Authors:  Jan Plzák; Lukás Lacina; Martin Chovanec; Barbora Dvoránková; Pavol Szabo; Zdenek Cada; Karel Smetana
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

4.  Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.

Authors:  Stephen B Keysar; Phuong N Le; Bettina Miller; Brian C Jackson; Justin R Eagles; Cera Nieto; Jihye Kim; Binwu Tang; Magdalena J Glogowska; J Jason Morton; Nuria Padilla-Just; Karina Gomez; Emily Warnock; Julie Reisinger; John J Arcaroli; Wells A Messersmith; Lalage M Wakefield; Dexiang Gao; Aik-Choon Tan; Hilary Serracino; Vasilis Vasiliou; Dennis R Roop; Xiao-Jing Wang; Antonio Jimeno
Journal:  J Natl Cancer Inst       Date:  2016-09-15       Impact factor: 13.506

5.  Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.

Authors:  Eric D Wirtz; Daisuke Hoshino; Anthony T Maldonado; Darren R Tyson; Alissa M Weaver
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-06       Impact factor: 6.223

6.  Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy.

Authors:  Jing-Hua Ren; Wen-Shan He; Li Nong; Qing-Yao Zhu; Kai Hu; Rui-Guang Zhang; Li-Li Huang; Fang Zhu; Gang Wu
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

Review 7.  CCL2 (monocyte chemoattractant protein-1) and cancer.

Authors:  Ilaria Conti; Barrett J Rollins
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

8.  Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma.

Authors:  Jian Gao; Sen Zhao; Trond S Halstensen
Journal:  Oncol Rep       Date:  2016-04-20       Impact factor: 3.906

9.  Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.

Authors:  Leilei Tao; Guichun Huang; Rui Wang; Yan Pan; Zhenyue He; Xiaoyuan Chu; Haizhu Song; Longbang Chen
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

10.  Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.

Authors:  Zejia Yang; Jipei Liao; Brandon A Carter-Cooper; Rena G Lapidus; Kevin J Cullen; Hancai Dan
Journal:  BMC Cancer       Date:  2019-05-22       Impact factor: 4.430

View more
  4 in total

Review 1.  Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas.

Authors:  Ana Belén Griso; Lucía Acero-Riaguas; Beatriz Castelo; José Luis Cebrián-Carretero; Ana Sastre-Perona
Journal:  Cells       Date:  2022-02-05       Impact factor: 6.600

2.  Advances in Cancer Metabolism and Tumour Microenvironment.

Authors:  Karel Smetana; Michal Masařík
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 5.923

Review 3.  In vitro models for head and neck cancer: Current status and future perspective.

Authors:  Christian R Moya-Garcia; Hideaki Okuyama; Nader Sadeghi; Jianyu Li; Maryam Tabrizian; Nicole Y K Li-Jessen
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

Review 4.  Cisplatin for cancer therapy and overcoming chemoresistance.

Authors:  Ranmali Ranasinghe; Michael L Mathai; Anthony Zulli
Journal:  Heliyon       Date:  2022-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.